Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Muti-center, Randomized, Double Blind, Positive Control Phase III Clinical Study to Evaluate the Efficacy and Safety of LZM012 in Moderate to Severe Chronic Plaque Psoriasis Patients

NCT06110676 is registered in ClinicalTrials.gov with Livzon Pharmaceutical Group Inc. as lead sponsor.

NCT NCT06110676
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06110676 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Muti-center, Randomized, Double Blind, Positive Control Phase III Clinical Study to Evaluate the Efficacy and Safety of LZM012 in Moderate to Severe Chronic Plaque Psoriasis Patients
Lead sponsor
Livzon Pharmaceutical Group Inc.
Phase
Phase 3
Overall status
Unknown status
Start date
August 21, 2023
Completion date
June 30, 2025
Enrollment
918 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis